Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 18, 2019Clinical Journal of the American Society of NephrologyOpen Access

Sodium Glucose Cotransporter 2 Inhibition Heralds a Call-to-Action for Diabetic Kidney Disease

View Full Paper
Ask AI
Bookmark
Share

Authors

KTKatherine R. TuttleProvidence Regional Medical Center EverettDCDavid Z. CherneyUniversity Health Network

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Tuttle et al. (2019) studied this question.

synapsesocial.com/papers/6a9cccc5a2aa65bfe097aa23https://doi.org/10.2215/cjn.07730719
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy2019 · 6,236 citations
  2. 2Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes2001 · 6,046 citations
  3. 3Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes2016 · 3,688 citations
  4. 4Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes2018 · 6,484 citations
  5. 5Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes2017 · 7,917 citations